Tratamiento de la enfermedad por cristales de pirofosfato cálcico

Although major advances have been made in the understanding of the pathogenesis, physiopathology and treatment of many rheumatic diseases, calcium pyrophosphate disease (CPPD) is a glaring omission, despite its high prevalence in rheumatology clinics. Current treatment schemes have not been tested in high quality trials and consequently clinicians’ decisions are based on clinical practice results. Non-steroidal anti-inflammatory drugs, colchicine and corticosteroids are the most widely used drugs, usually with success. However, in some patients, these drugs are ineffective, contraindicated or cannot be used because of side effects. In these patients, other drugs, such as methotrexate or antimalarials, may be useful.